.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC03_Anakinra.Anakinra .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC03_Anakinra.Anakinra| name: | Anakinra |
| ATC code: | L04AC03 | route: | subcutaneous |
| n-compartments | 1 |
Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1Ra) protein used for the treatment of rheumatoid arthritis and other autoinflammatory conditions. Anakinra blocks the biological activity of interleukin-1 by competitively inhibiting its binding to the interleukin-1 type I receptor (IL-1RI), and is approved for use in several countries.
Pharmacokinetic parameters reported for healthy adult volunteers (median age 32 years, range 20–44), single subcutaneous (s.c.) injection.
Urien, S, et al., & Quartier, P (2013). Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC pharmacology & toxicology 14 40–None. DOI:10.1186/2050-6511-14-40 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23915458
Liu, D, et al., & Jusko, WJ (2011). Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. Journal of pharmacokinetics and pharmacodynamics 38(6) 769–786. DOI:10.1007/s10928-011-9219-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/22002845
Dubinsky, S, et al., & Edginton, A (2024). Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support. Clinical pharmacokinetics 63(9) 1343–1356. DOI:10.1007/s40262-024-01424-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/39331235